Regorafenib after immunotherapy failure in advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer confirmed by a doctor or biopsy.
- You received immunotherapy (like atezolizumab plus bevacizumab, durvalumab plus tremelimumab, or nivolumab plus ipilimumab) and it either stopped working or had to be stopped due to side effects.
- You have at least one measurable tumor on a scan.
- Your liver function is moderately reduced (Child-Pugh class B, score 7-8).
- You are 19 years or older and has adequate blood counts and organ function.
- You have not had regorafenib before, and you have not received other treatments after stopping immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, regorafenib, for people with liver cancer that cannot be removed by surgery and who have already tried lenvatinib. The goal is to see if regorafenib can help control the cancer after lenvatinib stops working or causes too many side effects.
This study tests two oral targeted therapy drugs, lenvatinib and regorafenib, in people with advanced liver cancer (hepatocellular carcinoma) that has progressed after first-line immunotherapy-based treatment. The goal is to see if these drugs can control the cancer and improve outcomes.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of three treatments for advanced liver cancer that has not responded to immunotherapy: a chemotherapy delivered directly to the liver (HAIC), an immunotherapy drug (PD-L1), and a targeted therapy pill (Regorafenib). The goal is to see if this new combination can help control the cancer when the first immunotherapy stopped working.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Treatment Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.